Kornimate/medical-research-clean huggingface dataset:
dualsculpting the abdomen using coolsculpting

Conditions: Body Fat Disorder

Summary: evaluate the safety and efficacy of abdominal dualsculpting with cooladvantage applicators.

the study will evaluate the safety and efficacy of non-invasive fat reduction in the abdomen using two applicators.

Eligibility criteria:
inclusion criteria 1. male or female subjects \>22 years of age and \< 65 years of age. 2. subject who has been assessed to be eligible to receive multiple dualsculpting treatments on the abdomen using the cooladvantage and/or cooladvantage plus applicator. 3. no weight change exceeding 5% of body weight in the preceding month. 4. subject agrees to maintain his/her weight (i.e., within 5%) by not making any major changes in their diet or exercise routine during the course of the study. 5. subject has read and signed the study written informed consent form. exclusion criteria 1. subject has had a surgical procedure(s) in the area of intended treatmentsubject has had a surgical procedure(s) in the area of intended treatment. 2. subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the area of intended treatment. 3. subject has had a non-invasive fat reduction and/or body contouring procedure in the area of intended treatment within the past 12 months. 4. subject needs to administer, or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month. 5. subject has a known history of cryoglobulinemia, cold urticaria, cold agglutinin disease or paroxysmal cold hemoglobinuria. 6. subject has a known history of raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin. 7. subject has a history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising. 8. subject is taking or has taken diet pills or supplements within the past month. 9. subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites that may interfere with the treatment or evaluation (stretch marks is not an exclusion). 10. subject has an active implanted device such as a pacemaker, defibrillator, or drug delivery system or any other metal containing implant. 11. subject is pregnant or intending to become pregnant during the study period 12. subject is lactating or has been lactating in the past 6 months. 13. subject has a history of hernia in the areas to be treated. 14. subject is unable or unwilling to comply with the study requirements. 15. subject is currently enrolled in a clinical study of any other unapproved investigational drug or device. 16. any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
the development of a clinical test to assess the inflammatory phenotype of asthma

Conditions: Asthma

Summary: the purpose of this study is to determine the type and degree of inflammatory parameters in peripheral blood of asthma patients compared to analysis of induced sputum. 115 asthma patients visiting the outpatient clinic of the university medical center will be included. blood samples are obtained and sputum induction is performed. hypothesis: in asthma the analysis of type and degree of inflammation in peripheral blood by changes in phenotypes of leukocytes is at least as reliable as analysis of cells obtained from induced sputum

asthma is a heterogeneous disease and can be classified by level of control, disease severity and the inflammatory phenotype. however, these different domains overlap and classification of patients according to these characteristics has caused confusion in the literature. concerning the inflammatory phenotype international consensus is present regarding the diagnostic power of induced sputum. this methodology is, however, difficult to implement in general practice. local inflammation is associated with a complex combination of systemic pro- and anti-inflammatory signals that induce changes in responsive leukocytes. these changes can be used as read-out for type and degree of inflammatory disease. hypothesis: this will facilitate the diagnosis of inflammatory phenotypes in asthma, as general application of induced sputum is not feasible. goals 1. to investigate whether analysis of antibodies directed against active beta-1 and beta-2-integrins (cd29/cd18) and fcγrii (cd32) of primed eosinophils allows the diagnosis of eosinophilic asthma as compared to analysis of sputum eosinophilia. 2. to evaluate the applicability of antibodies against active β1/β2-integrins and fcγrii in symptomatic asthma patients as a test to diagnose eosinophilic and neutrophilic asthma. 3. to determine specific protein profiles in serum of asthma patients by proteomics for the development of a diagnostic test. 4. to evaluate the effectiveness of this new test in comparison with feno.

Eligibility criteria:
inclusion criteria: * adult asthma * aged 18-75 years * visiting the outpatient clinic of the umcu exclusion criteria: * smoking at present or in the last 12 months * past smoking history of \> 10 pack years * ab treatment for rti in past 4 weeks * abpa

Keywords: asthma inflammation phenotype sputum
new protocol with diluted citrate in continuous techniques

Conditions: Acute Renal Failure; Dialysis; Complications; Citrate Poisoning

Summary: the investigators designed a monitoring and control table of a citrate treatment on a specific monitor. this is the baxter "prismaflex" monitor, with 8.2 software version. dialysis bath liquids marketed by baxter: biphozyl are used. citrate liquid (1:18) regiocit is used. the dialysis treatment monitor (cvvhd) is programmed, with a blood / citrate pumps at a rate of 1:10 (1 ml / min of blood: 10 ml / h of dialysis fluid) the starting dose of citrate will be 3.5 mmol / l and the calcium compensation will be 100% working hypothesis: the patient undergoing citrate anticoagulation according to the designed algorithm will respond with ion stability and ph during the treatment, in addition to achieving an effective cleaning process.

study design: quasi-experimental design. two groups: 1. usual protocol with multifiltrate monitor and citrate (136 mmol/l) 2. intervention group. new protocol with prismaflex monitor and citrate (18 mmol/l) study population inclusión/exclusion criteria: adult patients (regardless of their underlying pathology), who develop acute renal failure, admitted to the icu of st pau hospital with the intensive medicine medical team, who require citrate anticoagulation in continuous dialysis therapy and are treated with baxter "prismaflex" monitor. patients who meet the criteria described above will be followed up in this study. expected sample size: it is estimated that with 24/12 (group1/2) patients will be enough to achieve our goal methodology. information sources: the start of the treatment with baxter citrate will be given according to the patient's need and subject to a basic medical decision. from here the research team will enter. the investigation team will never influence the medical decision. since such a treatment is started, the main investigator will assign a number to the dialysis circuit and will be followed, every six hours, for the most important variables. the rest of the variables will be collected at least once a day and according to the patient's situation.

Eligibility criteria:
inclusion criteria: * adult patients (regardless of their underlying pathology), who develop acute renal failure, admitted to the icu of st pau with the medical team of intensive medicine, who require anticoagulation with citrate in continuous dialysis therapy and are treated with the baxter monitor. exclusion criteria: * parenteral nutrition * pregnancy * cardiac surgery * coronary patients

Keywords: sodium citrate calcaemia magnesium phosphorus ionic calcium
monosialotetrahexosylganglioside sodium injection for prevention neurotoxicity of mfolfox 6 in mcrc

Conditions: Colorectal Cancer

Summary: the morbidity of colorectal cancer(crc) is 10%～15% in china.mfolfox6 has become one of the standard regimes for metastatic colorectal cancer (mcrc). neutropenia and oxaliplatin-induced neurotoxicity are the most common adverse effects which even result in discontinue of chemotherapy, especially for patients suffered from heavily acute neurotoxicity. monosialotetrahexosylganglioside is a component of membrane of nerve cells. previous phase ii clinical trial showed, it can reduce oxaliplatin-induced neurotoxicity(oin). but it did not certificated by phase iii trial. investigators designed the phase iii trial to investigate the effect and safety of monosialotetrahexosylganglioside sodium injection for prevention oin at colorectal cancer.

it is a placebo controlled phase iii trial. investigators plan to enroll 240 patients with 1:1 to a arm and b arm

Eligibility criteria:
inclusion criteria: 1. patients shall have normal organic function such as liver function, cardiac function and renal function; 2. age \>18 years old; 3. diagnosis mcrc with histology; 4. did not received first-line chemotherapy 5. karnofsky performance scores \>70 scores 6. should have target lesions or non-target lesions 7. for patients received oxaliplatin before, the residual neurotoxicity should less than grade 2 8. for diabetes without neuropathy, blood glucose before meal should less than 8mmol/l and hba1c\<7.0% 9. patients should be expected to live no shorter than 3 months exclusion criteria: 1. patients who is receiving chemotherapy; 2. wbc\ 1.5limitation;bun）\>1.5limitation；cr）\>1.5limitation；alt or ast\>2.5limitation（without liver metastasis）；alt or ast）\>5limitation（with liver metastasis）; 3. heart dysfunction; 4. brain metastasis; 5. peripheral nervous system or central nervous system abnormal including diabetes mellitus patients with neuropathy; 6. patients who received glutathione, acetylcysteine, calcium / magnesium, amifostine, carbamazepine, b vitamins, vitamin e within 30 days

Keywords: metastatic colorectal cancer neurotoxicity mfolfox6 monosialotetrahexosylganglioside sodium injection
construction and validation of a diagnostic model for predicting molecular residual disease and recurrence of cervical cancer based on circulating tumor hpv

Conditions: Cervical Cancer

Summary: systematic evaluation of the value of molecular residual lesions of cervical cancer based on circulating tumor hpv in the prognostic evaluation and recurrence monitoring of cervical cancer patients.

cervical cancer has a very clear etiology, with the vast majority of cases being caused by persistent and repeated infections with high-risk hpv. in the carcinogenic mechanism of cervical cancer, there are large amounts of hr-hpv integrated into the human genome in cancer cells; these hr-hpv can be released into the bloodstream in the form of cthpv, and most patients with stages i-iv of cervical cancer can have detectable cthpv in their blood. among them, the detection rate in the blood of late-stage patients ranges from 63.3% to 100%. several studies have demonstrated that cthpv may serve as a marker for monitoring recurrent tumor molecular residual lesions, which could be of significant importance for prognostic evaluation and monitoring whether the disease has recurred. in this study, we will systematically evaluate the value of molecular residual lesions of cervical cancer based on circulating tumor hpv in the prognostic evaluation and recurrence monitoring of cervical cancer patients

Eligibility criteria:
inclusion criteria: 1. women, aged between 18 and 75 years, can receive standard treatment, including patients who only receive surgery, and patients who receive radiotherapy and chemotherapy after surgery. 2. cervical cancer caused by hpv16 or hpv18 infection diagnosed by molecular biology or pathological tissue (p16), with pathological stage of ib1 to iv. - exclusion criteria: 1. patients with other malignancies 2. patients with any uncontrolled systemic disease, including active infection, uncontrolled hypertension, diabetes mellitus, unstable angina and congestive heart failure, myocardial infarction (1 year) before starting treatment, severe arrhythmia requiring medical treatment, coagulation abnormalities, liver or kidney or metabolic disease 3. cervical cancer patients who had undergone leep knife or conization in primary hospitals 4. cervical cancer patients whose peripheral blood was negative for cthpv at baseline. here, cthpv negative refers to patients who are both negative for ddpcr and ngs
ranibizumab 0.5 mg for diabetic macular edema with initial intensive treatment in the real world clinical setting in korea (rising k)

Conditions: Diabetic Macular Edema

Summary: this study was a multicenter, non-interventional, retrospective chart review of patients with dme who received ranibizumab 0.5 mg as initial intensive treatment in real-world clinical setting in korea. enrolled patients started receiving ranibizumab between 01 december 2019 and 31 october 2020, with records of receiving at least 3 doses in the first 4 months after starting treatment in the data collected until 30 april 2021. subsequent dosing interval was determined by the treating physician based on the patient's condition. data were collected for up to 24 weeks (±2 weeks) from the date of first dose of ranibizumab, including best-corrected visual acuity (bcva) and optical coherence tomography (oct) results at week 24. subjects were identified by review of patient medical records, and those who met the inclusion/exclusion criteria were enrolled. the primary objective of this study was to evaluate the effectiveness of ranibizumab in patients with dme who received initial intensive treatment by analyzing the mean change in bcva using data collected during the 24-week follow-up period. central subfield thickness (cst), intra-retinal fluid (irf), sub-retinal fluid (srf), edema improvement, and diabetic retinopathy severity scale (drss) results were also assessed to further analyze the effectiveness of ranibizumab. the total number of ranibizumab doses administered was obtained to determine the pattern of ranibizumab treatment in real-world clinical setting. all decisions regarding the clinical management and treatment of patients were made by the treating physician according to real-world routine practice, independently of the study. all data collected in this study were extracted from the patient medical records recorded in the process.


Eligibility criteria:
inclusion criteria: * aged ≥18 years at the start of ranibizumab treatment * diagnosed with diabetes mellitus (type 1 or type 2) * diagnosed with diabetic macular edema (dme) * vision loss due to dme as judged by treating physician * medical records of receiving at least 3 doses in 4 months (initial intensive treatment) since the first dose of ranibizumab between 01 december 2019 and 31 october 2020 (data up to 30 april 2021 were collected) * records of bcva and oct at baseline and week 24 (±2 weeks) after treatment with ranibizumab exclusion criteria: * contraindications to ranibizumab according to local label information * history of systemic or ocular anti-vegf therapy or loser photocoagulation in the last 90 days before the first dose of ranibizumab * history of intraocular or periocular corticosteroids in the last 120 days before the first dose of ranibizumab * history of vitrectomy
a study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual overactive bladder symptoms (oab) in men.

Conditions: Urinary Incontinence

Summary: a study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual oab symptoms in men.

a 2 arm study ( 1 active, 1 placebo) to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual oab symptoms in men

Eligibility criteria:
inclusion criteria: * symptoms of overactive bladder (oab) exclusion criteria: * current use of antimuscarinic therapy * evidence of a urinary tract infection

Keywords: treatment outcome urology solifenacin succinate urinary incontinence
exploring the effect of mindfulness on quality of life (qol) in spinal cord injury (sci)

Conditions: Spinal Cord Injuries; Quality of Life

Summary: the purpose of this study is to determine if practicing mindfulness breathing exercises has an effect on the overall health of persons with sci


Eligibility criteria:
inclusion criteria: * adult males and females aged 18-70 who are living with spinal cord injury * c5 to the t10 levels * self-reported american spinal cord injury association (asia) impairment scale (ais) a-d * eligible participants must be able to understand and provide consent, be in good health operationalized as free from acute treatable illness, pressure injury, and cardiovascular disease. exclusion criteria: * participants taking medications that alter chronotropic and pressor responses will be excluded. * pregnant women will not be eligible to participate
changes in reproductive and sexual health in people with early onset colorectal cancer

Conditions: Colorectal Cancer; Colorectal Neoplasms; Colorectal Carcinoma

Summary: the purpose of this study is to find out how cancer treatments (chemotherapy and/or radiation therapy) affect reproductive and sexual health in people with early onset colorectal cancer. the study researchers will observe and track changes in hormone levels and in sexual and reproductive health in people with early onset colorectal cancer. this information will help researchers know more about how cancer treatments affect reproductive and sexual health, including the ability to have children (fertility).


Eligibility criteria:
inclusion criteria: * 18-40 years of age and premenopausal (female) or 18-50 years of age (male) at time of diagnosis * histologic diagnosis of colorectal adenocarcinoma * able and willing to participate in the informed consent process * eligible for curative adjuvant or neoadjuvant therapy for colon or rectal cancer * willing and able to complete protocol questionnaires * rectal patients only: individuals who will be receiving chemotherapy, followed by chemoradiotherapy (chemort) exclusion criteria: * prior systemic treatment for this malignancy * active or prior secondary malignancy * history of ovarian resection (if female) * pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception until the termination of gestation, confirmed by a positive hcg laboratory test.

Keywords: early onset colorectal cancer colorectal cancer 21-035 memorial sloan kettering cancer center
diagnostic value of urinary indices in differentiating pre-renal and renal acute kidney injury

Conditions: Acute Kidney Injury

Summary: the study aims to evaluate the diagnostic value of urinary indices in differentiating pre-renal and renal acute kidney injury among critically ill patients.

critically ill patients with acute kidney injury (aki) will be included. urinary indices will be obtained immediately after defining aki, including specific gravity (sg), urine osmolarity (uosm), urine sodium (una), fractional excretion of sodium (fena), and fractional excretion of urea (feurea). the patterns of renal function and hemodynamic status serve as the clinical definition of pre-renal and renal aki. hemodynamic status will be evaluated at inclusion and followed during patients' icu stay. those who are hemodynamically stable at inclusion are classified as renal aki. those who are hemodynamically unstable at inclusion are followed until hemodynamic stabilization. those with aki recovery after hemodynamic stabilization are classified as pre-renal aki. those without aki recovery are defined as renal aki. urinary indices are measured again after hemodynamic stability. one of the investigators objectives is to evaluate the diagnostic value of urinary indices using recovery of renal function after hemodynamic stabilization as the definition of pre-renal aki. transesophageal echocardiography (tee) has been proved to be a reliable method of measuring left renal blood flow during surgical operation. decreased renal blood flow measured by tee may serve as an objective definition of pre-renal aki. the mesurement will be conducted at inclusion if the patient is sedated, intubated, and without tee contraindication. if the patient is hemodynamically unstable at inclusion, the measurement will be repeated after hemodynamic stabilization. the investigators study also serves the following aims: (1) feasibility of measuring renal blood flow by tee among critically ill patients; (2) the correspondence between renal blood flow measured by tee and clinical definition of pre-renal and renal aki; (3) the diagnostic value of urinary indices in differentiating pre-renal and renal aki, which is judged by renal blood flow measured by tee.

Eligibility criteria:
inclusion criteria: all patients admitted to medical icu of pumch with one of the following: * increase in serum creatinine by ≥ 26.5 umol/l within 48 hours; * increase in serum creatinine to ≥ 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; * urine volume \< 0.5ml/kg/h for 1 hour. exclusion criteria: * obstructive renal disease * renal replacement therapy (rrt) for chronic kidney disease

Keywords: acute kidney injury differential diagnosis urinary indices renal blood flow transesophageal echocardiography
metabolic effects of a green tea extract in multiple sclerosis patients

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: this study aims to investigate metabolic effects of a standardized green tea extract, containing a defined amount of epigallocatechin-3-gallate (egcg), in multiple sclerosis patients.


Eligibility criteria:
inclusion criteria: * patients with relapsing-remitting multiple sclerosis * stable treatment with glatiramer acetate at least 6 months prior to inclusion * expanded disability status scale \< 4.5 * normal weight, overweight exclusion criteria: * primary or secondary progressive forms of multiple sclerosis * clinically relevant heart, lung, liver, kidney diseases * habitual caffeine intake over 300 mg per day * habitual consumption of green tea * alcohol or drug abuse

Keywords: multiple sclerosis green tea extract metabolism